Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 13/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134394 | 0.90 | XDH (0.59) | XDH | |
| SCHEMBL17134328 | 0.85 | XDH (0.80) | XDH | |
| SCHEMBL17134084 | 0.83 | XDH (0.79) | XDH | |
| SCHEMBL17134280 | 0.82 | XDH (0.54) | XDH | |
| SCHEMBL17134461 | 0.82 | XDH (0.83) | XDH | |
| SCHEMBL17134322 | 0.81 | XDH (0.58) | XDH | |
| SCHEMBL17134077 | 0.81 | XDH (0.66) | XDH | |
| SCHEMBL17134333 | 0.81 | XDH (0.82) | XDH | |
| SCHEMBL17134357 | 0.81 | XDH (0.47) | XDH | |
| SCHEMBL17134233 | 0.79 | CA12 (0.49) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927219-B1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2018-05-30 | — | — | EP | disclosed |
| US-9802907-B2 | 2-aryl selenazole compound and pharmaceutical composition thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20150291543-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.(CN) (CN) | 2015-10-15 | — | — | US | disclosed |
| EP-2927219-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Atom Bioscience and Pharmaceutical Co. Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291543-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | SCLY, XDH, SELENOI | XDH 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.